ELF3 overexpression as prognostic biomarker for recurrence of stage II colorectal cancer

Ayumi Takaoka, Toshiaki Ishikawa, Satoshi Okazaki, Shuichi Watanabe, Fuyuki Miya, Tatsuhiko Tsunoda, Akifumi Kikuchi, Shinichi Yamauchi, Takatoshi Matsuyama, Masanori Tokunaga, Hiroyuki Uetake, Yusuke Kinugasa

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Background/Aim: Adjuvant chemotherapy for highrisk Stage II colorectal cancer (CRC) is weakly recommended; however, no consensus exists on "high-risk" definition. Prognostic biomarker identification is important for selecting patients with poor prognosis who may benefit from adjuvant chemotherapy. Materials and Methods: Using Microarray data analyses, ELF3 was identified as a candidate gene highly expressed in Stage II CRC with distant recurrences. ELF3 mRNA expression in 168 Stage II CRC patients was subjected to quantitative RT-PCR analysis and ELF3 protein expression in 185 patients was quantified by immunohistochemical analysis. The relationship between mRNA and protein expression levels and patient characteristics were also investigated. Results: The overall recurrence rate and relapsefree survival were significantly poorer in the ELF3 highexpression than the low-expression group at the mRNA and protein levels. High ELF3 mRNA and protein expression levels were independent poor prognostic factors. Conclusion: High ELF3 expression was associated with recurrence of Stage II.

Original languageEnglish
Pages (from-to)191-201
Number of pages11
JournalIn Vivo
Issue number1
Publication statusPublished - 2021 Jan
Externally publishedYes


  • Biomarker
  • ELF3
  • Microarray analysis
  • Prognostic marker
  • Stage II colorectal cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'ELF3 overexpression as prognostic biomarker for recurrence of stage II colorectal cancer'. Together they form a unique fingerprint.

Cite this